0.10
+0.003(+2.97%)
Currency In USD
Address
120 Presidential Way
Woburn, DE 01801
United States of America
Phone
781-245-1325
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
92
First IPO Date
October 29, 2021
| Name | Title | Pay | Year Born |
| Dr. Hermann Luebbert Ph.D. | Chief Executive Officer, President & Chairman | 784,789 | 1956 |
| Mr. Eugene Frederick Leffler III | Chief Financial Officer | 502,908 | 1985 |
| Mr. Jon Lyons M.B.A., Ph.D. | Vice President of Scientific & Medical Affairs | 0 | N/A |
| Ms. Erica F. Gates CPA, M.B.A. | Senior Director of Finance & Principal Accounting Officer | 0 | N/A |
| Mr. Daniel Hakansson J.D. | General Counsel & Head of Compliance | 0 | N/A |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.